Back to today’s briefing

Story perspectives

Genentech's Tenecteplase Receives FDA Approval for Acute Strokes

3/6/2025

41 6

Summary

Story summary

Genentech has received the green light for tenecteplase, a groundbreaking treatment for acute strokes that promises quicker administration. Administered within three hours of symptom onset, it’s crucial for patients to meet specific health criteria. Already FDA-approved for acute STEMI, tenecteplase will be marketed under various names worldwide, marking a significant advancement in emergency care.

1 of 1

Story summary

Genentech has received the green light for tenecteplase, a groundbreaking treatment for acute strokes that promises quicker administration. Administered within three hours of symptom onset, it’s crucial for patients to meet specific health criteria. Already FDA-approved for acute STEMI, tenecteplase will be marketed under various names worldwide, marking a significant advancement in emergency care.